中国肝脏病杂志（电子版）
中國肝髒病雜誌（電子版）
중국간장병잡지（전자판）
CHINESE JOURNAL OF LIVER DISEASES(ELECTRONIC VERSION)
2014年
2期
27-30
,共4页
付小义%张秀峰%林海华%彭雁忠
付小義%張秀峰%林海華%彭雁忠
부소의%장수봉%림해화%팽안충
肝炎,乙型,慢性%干扰素类%恩替卡韦
肝炎,乙型,慢性%榦擾素類%恩替卡韋
간염,을형,만성%간우소류%은체잡위
Hepatitis B chronic%Interferons%Entecavir
目的：观察应用个体化抗病毒路线图治疗HBeAg阳性慢性乙型肝炎的疗效及药品性价比。寻找符合国情的疗效好，价格便宜的治疗方案。方法在患者知情同意的情况下，选择符合条件的患者66例分为个体化组（36例）和对照组（30例）。个体化组依据路线图进行治疗，对照组初始干扰素联合恩替卡韦治疗。治疗24、48、72周及停药24周时进行生物化学、病毒学、血清学评估，应答疗效比较采用χ2检验。结果治疗24周，个体化组和对照组的HBsAg低于检测下限的比率，HBeAg低于检测下限的比率，HBV DNA低于检测下限的比率分别为11.1%，27.8%，38.9%和16.7%，40.8%，96.7%。对照组好于个体化组，但继续治疗至72周时，个体化组与对照组的HBsAg、HBeAg、HBV DNA低于检测下限的比率分别为30.6%、69.4%、97.2%和20%、43.3%、93.3%。两组比较HBeAg差异有统计学意义（P＜0.05），个体化组人均药品费用[（20000±5000）元]低于对照组[（30000±5000）元]。结论应用个体化路线图方案来治疗HBeAg阳性的慢性乙型肝炎患者不仅提高HBsAg、HBeAg低于检测下限的比率，还可为患者节省药品费用。
目的：觀察應用箇體化抗病毒路線圖治療HBeAg暘性慢性乙型肝炎的療效及藥品性價比。尋找符閤國情的療效好，價格便宜的治療方案。方法在患者知情同意的情況下，選擇符閤條件的患者66例分為箇體化組（36例）和對照組（30例）。箇體化組依據路線圖進行治療，對照組初始榦擾素聯閤恩替卡韋治療。治療24、48、72週及停藥24週時進行生物化學、病毒學、血清學評估，應答療效比較採用χ2檢驗。結果治療24週，箇體化組和對照組的HBsAg低于檢測下限的比率，HBeAg低于檢測下限的比率，HBV DNA低于檢測下限的比率分彆為11.1%，27.8%，38.9%和16.7%，40.8%，96.7%。對照組好于箇體化組，但繼續治療至72週時，箇體化組與對照組的HBsAg、HBeAg、HBV DNA低于檢測下限的比率分彆為30.6%、69.4%、97.2%和20%、43.3%、93.3%。兩組比較HBeAg差異有統計學意義（P＜0.05），箇體化組人均藥品費用[（20000±5000）元]低于對照組[（30000±5000）元]。結論應用箇體化路線圖方案來治療HBeAg暘性的慢性乙型肝炎患者不僅提高HBsAg、HBeAg低于檢測下限的比率，還可為患者節省藥品費用。
목적：관찰응용개체화항병독로선도치료HBeAg양성만성을형간염적료효급약품성개비。심조부합국정적료효호，개격편의적치료방안。방법재환자지정동의적정황하，선택부합조건적환자66례분위개체화조（36례）화대조조（30례）。개체화조의거로선도진행치료，대조조초시간우소연합은체잡위치료。치료24、48、72주급정약24주시진행생물화학、병독학、혈청학평고，응답료효비교채용χ2검험。결과치료24주，개체화조화대조조적HBsAg저우검측하한적비솔，HBeAg저우검측하한적비솔，HBV DNA저우검측하한적비솔분별위11.1%，27.8%，38.9%화16.7%，40.8%，96.7%。대조조호우개체화조，단계속치료지72주시，개체화조여대조조적HBsAg、HBeAg、HBV DNA저우검측하한적비솔분별위30.6%、69.4%、97.2%화20%、43.3%、93.3%。량조비교HBeAg차이유통계학의의（P＜0.05），개체화조인균약품비용[（20000±5000）원]저우대조조[（30000±5000）원]。결론응용개체화로선도방안래치료HBeAg양성적만성을형간염환자불부제고HBsAg、HBeAg저우검측하한적비솔，환가위환자절성약품비용。
Objective To observe treatment of HBeAg positive chronic hepatitis B with individual antiviral efifcacy and drug price roadmap. To look for a suitable, effective and inexpensive treatment. Methods After patients are informed consent, 66 eligible patients, were divided into individual group 36, control group 30. Individual group is treated according to the roadmap treatment, the control group with interferon and entecavir treatment initially. The biochemical, virological, serological indicators at week 24, week 48, week 72 and week 24 after drug withdrawal were evaluated, response efifcacy was compared withχ2 test. Results HBsAg negative rate, HBeAg negative conversion rate, HBV DNA seroconversion rates of individual group and control group at week 24 were 11.1%, 27.8%, 38.9%and 16.7%, 40.8%, 96.7%, the control group was better than the individual group. But at week 72, HBsAg negative rate, HBeAg negative conversion rate, HBV DNA seroconversion rates of individual group and control were 30.6%, 69.4%, 97.2%and 20%, 43.3%, 93.3%. There is signiifcant difference between two groups HBeAg (P<0.05), individual group and the control group, the average cost of drugs are (20000 ± 5000) yuan and (30000 ± 5000) yuan. Conclusions The use of individual road map plan to the treatment of HBeAg positive chronic hepatitis B can improve HBsAg, HBeAg negative conversion rate, but also save the cost of drugs, but it is need randomized clinical trials for larger sample size to prove.
